BTG granted Ohara exclusive development and commercialization rights to Voraxaze glucarpidase in Japan

BTG plc

U.K. / Mid-Cap Biopharma ($1-$50 billion)

$1,554.1m on 12/09/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Ohara Pharmaceutical Co. Ltd.

Japan / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced